David S. Snyder, MD, discusses using ruxolitinib to prevent patients receiving stem cell transplantation from developing graft versus host disease.
David S. Snyder, MD
Advertisement
Articles by David S. Snyder, MD
Advertisement
Latest Updated Articles
Ruxolitinib Used to Prevent GVHD Throughout Stem Cell TransplantationPublished: September 13th 2019 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
